Press Releases from InDex Pharmaceuticals (7 total)
InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Res …
Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a Japanese patent by the Japan Patent Office (JPO). The patent…
Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ul …
- InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases -
Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of…
InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member
- Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network -
Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke…
InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant …
Stockholm, April 26, 2012 – InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The…
InDex Pharmaceuticals Expands Management Team
- InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer -
Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced…
InDex Pharmaceuticals Develops Companion Diagnostic Test for New Ulcerative Coli …
- Personalized treatment option for patients with refractory ulcerative colitis -
Stockholm, March 20, 2012 - InDex Pharmaceuticals today announced the development of a companion diagnostic…
InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct®
-- TLR9 Agonist for the Treatment of Chronic, Active, Treatment-Refractory Ulcerative Colitis --
Stockholm, March 6, 2012 - InDex Pharmaceuticals today announced the start of the…
Go To Page:
